✦ LIBER ✦

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

✍ Scribed by Geller, Melissa A.; Cooley, Sarah; Judson, Patricia L.; Ghebre, Rahel; Carson, Linda F.; Argenta, Peter A.; Jonson, Amy L.; Panoskaltsis-Mortari, Angela; Curtsinger, Julie; McKenna, David; Dusenbery, Kathryn; Bliss, Robin; Downs, Levi S.; Miller, Jeffrey S.

Book ID: 121713036
Publisher: Informa plc
Year: 2011
Tongue: English
Weight: 277 KB
Volume: 13
Category: Article
ISSN: 1465-3249
DOI: 10.3109/14653249.2010.515582

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of weekly topotecan and

A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers

✍ Divya Gupta; Ricky L. Owers; Mimi Kim; Dennis Yi-Shin Kuo; Gloria S. Huang; Shoh 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 189 KB

969 ADOPTIVE IMMUNOTHERAPY WITH ALLOGENO

969 ADOPTIVE IMMUNOTHERAPY WITH ALLOGENOUS NATURAL KILLER CELLS: RESULTS OF A PHASE-I/II TRIAL IN PATIENTS WITH METASTATIC KIDNEY CANCER

✍ C. Doehn; A.J. Meyer; L. Walle; A. Behm; D. Jocham; C. Frohn 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 316 KB

A Phase II study of trabectedin single a

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

✍ Krasner, C N; McMeekin, D S; Chan, S; Braly, P S; Renshaw, F G; Kaye, S; Provenc 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 137 KB

A phase II and pharmacodynamic study of

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

✍ Edwin M. Posadas; Meghan S. Liel; Virginia Kwitkowski; Lori Minasian; Andrew K. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

## Abstract ## BACKGROUND The primary objective of this study was to evaluate the biochemical effects of gefitinib on its target signal‐transduction pathways in patients with recurrent epithelial ovarian cancer (EOC). The secondary objectives included assessing clinical activity and toxicity and d

The PACOVAR-trial: A phase I/II study of

The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer

✍ Michael Eichbaum; Christine Mayer; Regina Eickhoff; Esther Bischofs; Gerhard Geb 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 191 KB

Enhancement of natural killer cell activ

Enhancement of natural killer cell activity and 2-5A synthetase in operable breast cancer patients treated with polyadenylic; polyuridylic acid

✍ Ara G. Hovanessian; Jung Koo Youn; Claudine Buffet-Janvresse; Yves Riviere; Mich 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 618 KB